O 1 P E C C MAY 2 9 2001

RECEIVED

		( MA	ليبر 2 9 2001		R	EUEIV		
<del></del>		- \ <del>2</del>	<u>````</u>	ATTORNEY'S DK	I NO.	SHE TIVARREIGN HON-	FT <sub>1</sub> 1	OF _4
INFORMATION DISCLOSURE CITATION				017753-122		09/462,993		
				O17753-122 O9/462,993 APPLICANT TECH CENTER 1600/2900  FILING DATE GROUP				
	DTO	4440		FILING DATE April 17, 2000		GROUP Unassigned	10	7
	PTO-		J.S. PATENT			Onassigned		
EXAMINER'S						T T	FILING	DAT
INITIALS	PATENT NO.	DATE	NAME		CLASS	SUBCLASS		
						<u> </u>	-	
			DEIGN DATEN	T DOOLINGENIC				
EXAMINER'S	T	FOI	KEIGN PATEN	T DOCUMENTS	1	1	Trans	slation
INITIALS	PATENT NO.	DATE	<del></del>	COUNTRY	CLASS	SUBCLASS	Yes	No
	90/10459	9/90	<del>WO</del>				ļ <u>.</u>	
MUP .	93/02184	2/93	wo				ļ 	
rep	85 09480	12/86	FR					
	OTHER DOO	CUMENTS (In	cluding Auth	or, Title, Date, Pe	rtinent Pag	jes, Etc.)		
per	Pfister, 1987, edition, Plenu			The Papillomavir 1-38	uses, Salzı	man and Ho	wley	
1	Schlaegel et al, 1986, Science 233, 464-467							
	Kanda et al, 1988, J. Virol. 62, 610-613							
	Vousden et al	, 1988, Onc	ogene Res. 3	3, 1-9				
	Bedell et al, 1987, J. Virol. 61, 3635-3640							
	Munger et al,	1989, EME	3O J. 8, 4099	9-4105				
	Heck et al, 19	992, Proc. N	Vatl. Acad. S	ci. USA 89, 444	2-4446			
	Crook et al, 1991, Cell 67, 547-556							
	Miki et al, 19	94, Science	226, 66-71					
	Wooster et al, 1995, Nature 378, 789-792							
	Hareuveni et	al, 1990, Pr	oc. Natl. Ac	ad. Sci. USA 87	, 9498-950	)2		
	Branden and	Tooze, 1991	, Introductio	n to Protein Stru	cture, p. 2	202-214, NY	, Garl	land
	Zhou et al, 19	991, Virolog	y 185, 625-6	532				
	Tobery and S	iliciano, 199	7, J. Exp. M	led. 5, 909-920				
	Kaisho et al,	1997, Scienc	ce 276, 412-4	114				
	Mochamer an	d Rose, 198	7, J. Cell Bio	ol. 105, 1205-12	14			
	Mochamer, 19	993, Curr. (	Opin. Cell Bi	ol. 5, 606-612				
EXAMINER	<u> </u>			DATE CONSIDERI	FD	a)		
	11 _		] '	CHIL COMUDEN	1-1-0	01		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.

RECEIVED

						MANY SHEE	T <u>2</u>	OF _4
			017753-12	2	OS/462 OS3			
OVREORMATION DISCLOSURE				APPLICANT TECH CENTER 1600/2900				
ľ	② CITA	TION		Marie-Paule	KIENY et al			·
MAY 2 9 2001 PTO-1449				FILING DATE April 17, 20	000	GROUP 1632		
(3)	**/ F1041		.S. PATENT (					
EXAMINERS	EXAMPLES U.S. FATENT					Γ	FILING	DATE
INITIALS	PATENT NO.	DATE		NAME	CLASS	SUBCLASS		
EXAMINER'S INÍTIALS	PATENT NO. DATE			COUNTRY	CLASS	SUBCLASS	Trans Yes	No
Me	94/28152	12/94	wo					
<del>''</del>	96/17070	6/96	wo					<del>                                     </del>
	94 08300	1/96	FR		$\top$			<del>                                     </del>
U	83 286	7/83	EP					<del>                                     </del>
	OTHER DOC	UMENTS (In	cluding Autho	or, Title, Date,	Pertinent Pag	es, Etc.)		
pos	Ensinger et al	l, 1972, J. Virol. 10, 328-339						
	Ketner et al,	1989, Nucle	ic Acids Res.	17, 3037-30	48			
	Gooding et al, 1990, Critical Review of Immunology, 10, 53-71							
	Freeman et al, 1989, J. of Immunology 143, 2714-2722							
	Taniguchi et a	al, 1983, Na	ture 302, 305	5-311				
	Phelps et al, 1992, J. Virol. 66, 2418-2427							
	Graham and Prevect, 1991, Methods in Molecular Biology, Vol. 7, p. 109-128							
	Naviaux and Verma, 1992, Current Opinion in Biotechnology 3, 540-547							
	Meyer et al, 1991, J. Gen. Virol. 72, 1031-1038							
	Sutter et al, 1994, Vaccine 12, 1032-1040							
	Chen et al, 1995, J. Clin. Invest. 96, 2775-2782							
	Vile et al, 199	3, Cancer F	Res. 53, 3860	-3864				
	Harris et al, 1	994, Gene 7	Therapy 1, 17	70-175				
					97	•		
	Chakrabarti et al, 1997, Biotechniques 23, 1094-1097  Hammond et al, 1997, J. Virological Methods 66, 135-138							
	Kumar and Bo	oyle, 1990, '	Virology 179	, 151-158				
	-	<u> </u>			2, 115-121			
	Felgner et al, 1989, Proc. West. Pharmacol. Soc. 32, 115-121  Hodgson and Solaiman, 1996, Nature Biotechnology 14, 339-342							
	Remy et al, 19							
<del>-</del>	Lynch et al, 1	<del>`</del>						
EXAMINER	1/-			DATE CONSID	ERED 6.)-4	7)		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

							「C (See	WE	<b>qF)</b> 4	
ONFORMATION DISCLOSURE					ATTORNEY'S DKT NO. 017753-122		APPLICATION NO. 09/462,993 2001			
CITATION					APPLICANT Marie-Paule KIENY et al TECH CENTER 1600/2900					
1/					FILING DATE	r et al	GROUP	1600/2	<del>90<b>0</b> –</del>	
MAY 2 9 2001   PTO-1449					April 17, 2000		1632			
(A)	Wet 53	U	.S. PATENT	DC	CUMENTS					
EXAMINER'S INITIALS	PATENT NO. DATE		N	IAME	CLASS	SUBCLASS	FILING	DATE		
rup	5,185,146									
		FOR	EIGN PATEN	UT I	DOCUMENTS					
EXAMINER'S	DATENT NO	DATE	COUNTRY		LINITOV	CLASS	SUBCLASS	Trans	lation No	
LUP	97/04119	2/97	wo		ONTRI	CLASS	JOBELAGO	Tes	110	
1	2,583,429	12/86	FR				<del>  / -</del>		<del> </del>	
<b></b>			ļ · · · · · · · · · · · · · · · · · · ·		<del></del>	<del>                                     </del>	<i>/</i>			
	206 920	12/86	EP							
V	0 305 229	3/89	EP							
	OTHER DOC	UMENTS (In	cluding Auth	or,	Title, Date, Perti	nent Pag	es, Etc.)		1	
reg	Brasel et al, 1				<u> </u>				************	
	Marakovsky et al, 1996, J. Exp. Med. 184, 1953-1962								****	
	Graham et al, 1977, J. Gen. Virol. 36, 59-72  Imler et al, 1996, Gene Therapy 3, 75-84									
									•	
	Yeh et al, 1996, J. Virol. 70, 559-565									
	Krougliak and Graham, 1995, Human Gene Therapy 6, 1575-1586									
<u> </u>	Wang et al, 1995 Gene Therapy 2, 775-783									
	Mayr et al, 1	975, Infectio	n 3, 6-14							
Msf	Sutter and Moss, 1992, Proc. Natl. Acad. Sci. USA 89, 10847-10851									
	Katz et al, 1997, AIDS Res. Hum. Retrov. 13, 1497-1500									
	BJ 5183, Hanahan, 1983, J. Mol. Biol. 166, 557-580									
	Bubeck et al, 1993, Nucleic Acid Res. 21, 3601-3602  Mackett et al, 1982, Proc. Natl. Acad. Sci. USA 79, 7415-7419							<del>.</del>		
	Mackett et al, 1984, J. Virol. 49, 857-864  Zhou et al, 1991, Virology 185, 251-257									
	Altenburger e	<del></del>					· · · · · · · · · · · · · · · · · · ·			
<del>                                     </del>	Kieny et al, 1			10	15, 15-27				<del></del>	
<del></del>	ixiony ot ai, i	.703, Gene 2	O, 71-33							
EXAMINER	1			DA	ATE CONSIDERED	6-1.	-0)			
	1/1/			L		<u> </u>	•			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance  $\underline{\text{and}}$  not considered. Include copy of this form with next communication to applicant.

RECEIVED 4

ONFE	RMATION	DISCLO	SURE	ATTORNEY'S DKT NO. 017753-122		ARPHICATION NO. 09/462,993 2001		
MAY 2 9 2	CITA	ΓΙΟΝ		FILING DATE		CH CENTER 1600/2900		
MAT 2 3 3	ိုး ဦး PTO-1	0.0000000000000000000000000000000000000		April 17, 2000		1632		
EXAMINEADE			I.S. PATENT	DOCUMENTS	T	Τ	FILING DATE	
INITIALS	PATENT NO.	DATE		NAME	CLASS	SUBCLASS	<del> </del>	
	<u> </u>							
		FOF	REIGN PATEN	IT DOCUMENTS		1		
EXAMINER'S INITIALS	PATENT NO.	DATE		COUNTRY	CLASS	SUBCLASS	Translation Yes No	
Nep	97 05203	10/98	FR	COOKINI	CLASS	GODELAGO	res No	
/		·						
-			-					
				7. 7				
	OTHER DOC	LIBATNITO (I-	aladia A.A.	or, Title, Date, Pe	-diama Dan	l		
per				ol. 210, 749-769		95, E(C.)		
<u> </u>	· · · · · · · · · · · · · · · · · · ·			ol. 210, 771-784				
1	Faulkner and							
V	Lathe et al, 19	87, Gene 5	7, 193-201	***				
EXAMINER	1			DATE CONSIDER	ED 6.7-6	7)		
	W				6.1-0	1		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.